{
    "pmcid": "8420576",
    "qa_pairs": {
        "How do the nanobodies maintain their neutralization capabilities against RBD variants with immune-escape mutations?": [
            "Through structural adaptations that accommodate changes in the RBD",
            "By binding to multiple sites on the virus simultaneously",
            "By increasing their size to cover more of the viral surface",
            "Through chemical modifications that enhance binding strength"
        ],
        "What is the primary target of the nanobodies developed in the study for neutralizing SARS-CoV-2?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein of the virus",
            "The membrane protein of the virus",
            "The envelope protein of the virus"
        ],
        "What method was used to gain detailed structural insights into the binding interactions between nanobodies and the RBD?": [
            "X-ray crystallography and cryo-EM studies",
            "Nuclear magnetic resonance (NMR) spectroscopy",
            "Atomic force microscopy",
            "Fluorescence resonance energy transfer (FRET)"
        ],
        "What property of the nanobodies makes them suitable for production, storage, and transport?": [
            "Hyperthermostability, withstanding temperatures up to 95\u00b0C",
            "Ability to bind multiple viral proteins simultaneously",
            "Capability to integrate into host cell membranes",
            "Resistance to enzymatic degradation in the bloodstream"
        ],
        "Which technique was used to select high-affinity nanobody binders from immune libraries?": [
            "Phage display techniques",
            "Yeast two-hybrid screening",
            "Surface plasmon resonance",
            "Mass spectrometry"
        ]
    }
}